| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T17140 | ||||
| Target Name | P2X purinoceptor 3 | ||||
| Target Type | Clinical Trial |
||||
| Drug Potency against Target | Cyclic LVVYPWT | Drug Info | IC50 = 82.4 nM | [528976] | |
| ISOPPADS | Drug Info | IC50 = 74 nM | [526106] | ||
| AVVYPWT | Drug Info | IC50 = 14.3 nM | [528976] | ||
| LAVYPWT | Drug Info | IC50 = 32.4 nM | [528976] | ||
| References | |||||
| Ref 528976 | J Med Chem. 2007 Sep 6;50(18):4543-7. Epub 2007 Aug 3.Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. | ||||
| Ref 526106 | J Med Chem. 2001 Feb 1;44(3):340-9.Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. | ||||
| Ref 528976 | J Med Chem. 2007 Sep 6;50(18):4543-7. Epub 2007 Aug 3.Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. | ||||
| Ref 528976 | J Med Chem. 2007 Sep 6;50(18):4543-7. Epub 2007 Aug 3.Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.